Merck & Company, Inc.
MRK · NYSE
- Prev Close
- $128.00
- Market Cap
- $318.21B
- Open
- —
- Trailing P/E
- —
- Day Range
- $131.07 - $127.56
- 52W Range
- $135.05 - $77.58
- Forward P/E
- —
- EPS
- —
- Volume
- 4.80M
- Dividend Yield
- —
About Merck & Company, Inc.
Merck sells prescription medicines and vaccines, with its portfolio centered on oncology, infectious disease and prevention. The supplied evidence highlights oncology products, newer products, Keytruda strength, Gardasil challenges, and HIV treatment and prevention, including a weekly oral regimen and monthly PrEP opportunity. It earns revenue from product sales to healthcare providers and patients through medical channels; the evidence does not provide a segment contribution split. Merck generated $65.0 billion of revenue and $18.3 billion of net income in fiscal 2025, up from $64.2 billion and $17.1 billion, respectively, in 2024.
Notable Price Movement
- Aug 3-7$128.001.69%
-2.90%, from $131.82 to $128.00. Merck declined through July 30, briefly recovered to $130.20 on July 31, then fell 1.87% to $127.77 on August 3 before edging up to $128.00 on August 4. The only identified company-specific catalyst was second-quarter reporting: Merck beat earnings and revenue estimates, raised and narrowed its 2026 sales outlook, and cited strong oncology and newer-product performance. Those positives were tempered by a $1.3 billion GAAP quarterly loss, versus $4.4 billion of profit a year earlier, and a $0.54 loss per share. Because the largest decline preceded the August 4 release, the supplied evidence does not establish that the earnings details caused the weekly drop.
Stories & Analysis
SCHD, BEX: Big ETF InflowsCompared to Estimates, Merck (MRK) Q2 Earnings: A Look at Key MetricsMerck & Co Q2 26 Earnings Conference Call At 9:00 AM ETMerck (MRK) Reports Q2 Loss, Beats Revenue Estimates
